Autolus Therapeutics plc (AUTL) has entered 2026 with clear momentum, driven by the commercial progress of its first approved therapy, AUCATZYL (obe-cel), and a pipeline that continues to expand into new indications. With sales in its debut year surpassing expectations, regulatory approvals secured across major markets, and multiple clinical programs advancing toward pivotal stages, the company is shaping a path that combines near-term revenue growth with long-term opportunities. These developments make AUTL a stock that stands out at this moment, supported by both commercial traction and scientific progress.
Momentum Drivers & Upcoming Milestones
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.